Related Experiment Video
Updated: May 9, 2026
10:41
Analysis of Cerebral Vasospasm in a Murine Model of Subarachnoid Hemorrhage with High Frequency Transcranial Duplex Ultrasound
Published on: June 3, 2021
Cerebral arterial thrombosis in ulcerative colitis
Giovanni Casella1, Claudio Camillo Cortelezzi, Delodovici Marialuisa
1Medical Department, Desio Hospital, Via Mazzini, 20033 Desio Monza e Brianza, Italy.
Case Reports in Gastrointestinal Medicine
|July 19, 2013
Summary
Inflammatory bowel disease (IBD) can cause rare arterial thrombosis. A young man with ulcerative colitis experienced a cerebral artery clot, successfully treated with intraarterial thrombolysis.
Area of Science:
- Gastroenterology
- Neurology
- Vascular Medicine
Background:
- Thrombosis is a known, though uncommon, extraintestinal manifestation of inflammatory bowel disease (IBD).
- Venous thromboembolism is more frequently associated with IBD than arterial events.
- Inflammatory bowel disease encompasses conditions like ulcerative colitis and Crohn's disease.
Purpose of the Study:
- To report a rare case of arterial thrombosis in a patient with ulcerative colitis and sclerosing cholangitis.
- To highlight the potential for cerebral arterial thrombosis as an extraintestinal manifestation of IBD.
- To review the existing literature on arterial thrombosis in IBD patients.
Main Methods:
- Case report of a 25-year-old Caucasian male with ulcerative colitis and sclerosing cholangitis.
- Description of an episode of right middle cerebral arterial thrombosis.
- Intervention with intraarterial thrombolysis for clot resolution.
Main Results:
- Successful resolution of right middle cerebral arterial thrombosis following intraarterial thrombolysis.
- The patient had coexisting ulcerative colitis and sclerosing cholangitis.
- The arterial thrombosis was considered an extraintestinal manifestation of IBD.
Conclusions:
- Arterial thrombosis, including cerebral events, can occur in patients with inflammatory bowel disease.
- Intraarterial thrombolysis is a viable treatment option for acute cerebral arterial thrombosis in IBD patients.
- Further research is warranted to understand the mechanisms and prevalence of arterial thrombosis in IBD.
Related Concept Videos
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
01:20Inflammatory Bowel Disease IV: Clinical Manifestations
Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...
01:26Inflammatory Bowel Disease I: Introduction
Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...
01:17Chronic Bowel Disorders: Introduction
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.